A commercial stage pharmaceutical company with three revenue generating pharmaceutical products
Development pipeline targeting large medical needs
AmorphOX® - a novel world leading nasal delivery technology leading to a new wave of products
Key News
NOVEMBER 30, 2023
Interview with Robert DeLuca, President of Orexo US Inc. on the OUD market and expanding the product portfolio
NOVEMBER 28, 2023
FDA has accepted the New Drug Application filing for OX124
NOVEMBER 2, 2023
Orexo Q3 2023 Interim Report
To read all NEWS go to Media in the top menu
Key financial figures
Group net revenue
629 MSEK
Last Twelve Months, Q422-Q323
Group EBITDA
-98 MSEK
Last Twelve Months, Q422-Q323
US Pharma segment EBIT
285 MSEK
Last Twelve Months, Q422-Q323
Cash position
184 MSEK
Q323